Loading…
Sectoral / Thematic · Nippon India Mutual Fund · AMFI code 102431Nippon India Pharma Fund
Disclosed for 84 months, Sep 2019 to Aug 2026.Published as: NIPPON INDIA PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹5,397 Cr
up ₹173 Cr vs Nov 2021
- Stocks held
- 23
- unchanged
- Top 10 weight
- 73.7%
Nippon India Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In December 2021 it disclosed 23 stocks worth ₹5,397 Cr, up ₹173 Cr from Nov 2021. Its largest positions were Sun Pharmaceutical Industries Limited (11.9%), Dr. Reddy's Laboratories Limited (9.5%), Cipla Limited (8.7%); the ten largest together made up 73.7% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 76.5% of its equity. Cash and debt stood at 0.9%. Compared with Nov 2021 the fund entered 0 new stocks and exited 0.
Against 226 other Sectoral / Thematic funds
Concentration
96%
Top-10 weight is higher than 96% of peers
Breadth
5%
Holds more stocks than 5% of peers
Cash
13%
Holds more cash than 13% of peers
What these mean: concentration · cash
Holdings in December 2021
Download CSVEvery line the fund disclosed, with the change against Nov 2021. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 11.91% | up 0.95 pts | ₹643 Cr | up ₹70 Cr | Added |
| Dr. Reddy's Laboratories Limited | 9.55% | up 0.15 pts | ₹515 Cr | up ₹24.3 Cr | Added |
| Cipla Limited | 8.75% | up 0.38 pts | ₹472 Cr | up ₹35 Cr | Added |
| Aurobindo Pharma Limited | 7.62% | up 0.67 pts | ₹411 Cr | up ₹48.1 Cr | Added |
| Lupin Limited | 7.40% | up 2.15 pts | ₹399 Cr | up ₹125 Cr | Added |
| Divi's Laboratories Limited | 6.93% | down 0.54 pts | ₹374 Cr | down ₹16 Cr | Trimmed |
| Torrent Pharmaceuticals Limited | 5.77% | up 0.53 pts | ₹312 Cr | up ₹37.7 Cr | Added |
| Narayana Hrudayalaya Limited | 5.76% | up 0.11 pts | ₹311 Cr | up ₹15.5 Cr | Added |
| Apollo Hospitals Enterprise Limited | 5.35% | down 1.19 pts | ₹289 Cr | down ₹53 Cr | Trimmed |
| Abbott India Limited | 4.65% | down 0.06 pts | ₹251 Cr | up ₹5.1 Cr | Added |
| Gland Pharma Limited | 4.04% | down 0.10 pts | ₹218 Cr | up ₹1.6 Cr | Added |
| Thyrocare Technologies Limited | 3.84% | down 0.09 pts | ₹207 Cr | up ₹2.2 Cr | Added |
| Fortis Healthcare Limited | 3.77% | up 0.01 pts | ₹203 Cr | up ₹6.8 Cr | Added |
| Sanofi India Limited | 3.15% | down 0.04 pts | ₹170 Cr | up ₹3.6 Cr | Added |
| Zydus Lifesciences Limited | 2.24% | down 0.43 pts | ₹121 Cr | down ₹18.8 Cr | Trimmed |
| Indoco Remedies Limited | 1.96% | up 0.23 pts | ₹106 Cr | up ₹15.4 Cr | Added |
| Vijaya Diagnostic Centre Limited | 1.63% | up 0.21 pts | ₹87.9 Cr | up ₹13.7 Cr | Added |
| Pfizer Limited | 1.27% | up 0.02 pts | ₹68.4 Cr | up ₹3.3 Cr | Added |
| Alkem Laboratories Limited | 1.25% | up 0.38 pts | ₹67.7 Cr | up ₹22.1 Cr | Added |
| Cash, TREPS & receivables | 0.89% | down 3.19 pts | ₹47.9 Cr | down ₹165 Cr | Trimmed |
| Orchid Pharma Limited | 0.73% | down 0.02 pts | ₹39.5 Cr | down ₹2 L | Held |
| Jubilant Pharmova Limited | 0.60% | down 0.02 pts | ₹32.3 Cr | up ₹15 L | Held |
| Tarsons Products Limited | 0.51% | down 0.06 pts | ₹27.8 Cr | down ₹2.3 Cr | Trimmed |
| Healthcare Global Enterprises Limited | 0.44% | down 0.04 pts | ₹23.9 Cr | down ₹1.4 Cr | Trimmed |
What changed, Nov 2021 to Dec 2021
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Lupin Limitedup ₹125 Cr (+2.15% pts)
- Sun Pharmaceutical Industries Limitedup ₹70 Cr (+0.95% pts)
- Aurobindo Pharma Limitedup ₹48.1 Cr (+0.67% pts)
- Torrent Pharmaceuticals Limitedup ₹37.7 Cr (+0.53% pts)
- Cipla Limitedup ₹35 Cr (+0.38% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Nov 2021, the weight rose most in Pharmaceuticals & Biotechnology (+1.6 pts) and Pharmaceuticals (+0.2 pts), and fell most in Healthcare Services (−1.7 pts).
- Pharmaceuticals & Biotechnology74.9% → 76.5%+1.6 pts
- Pharmaceuticals1.8% → 2.0%+0.2 pts
- Healthcare Services22.7% → 21.0%−1.7 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Dec 2020 | Jun 2021 | Sep 2021 | Nov 2021 | Dec 2021 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 79.4% | 76.3% | 76.1% | 74.9% | 76.5% |
| Healthcare Services | 18.2% | 20.6% | 21.8% | 22.7% | 21.0% |
| Pharmaceuticals | 2.4% | 2.3% | 2.1% | 1.8% | 2.0% |
| Healthcare Equipment & Supplies | — | — | — | 0.6% | 0.5% |
Allocation in Dec 2021change vs Nov 2021
- Pharmaceuticals & Biotechnology (15)76.5%▲ 1.6 pts
- Healthcare Services (6)21.0%▼ 1.7 pts
- Pharmaceuticals (1)2.0%▲ 0.2 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Dec 2021
0.9%
▼ 3.2 pts vs Nov 2021
- Cash alone
- 0.9%
- cash and net receivables
- A year earlier
- 2.3%
- Dec 2020 · now ▼ 1.4 pts
- Last 12 months
- 0.6% – 5.9%
- lowest to highest · record 5.9% in May 2021
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.